All In Biotech

Drug Trial Radar · NCT04691661

Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease

A Randomized Double-blind Placebo-controlled Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Radotinib in Parkinson's Disease

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

43

Actual

Start

Sep 9, 2021

Primary completion

Sep 2, 2026

Study completion Apr 30, 2027

Sponsor

Lead sponsor
Il-Yang Pharm. Co., Ltd.Industry
Sponsor type
Industry
First posted
Dec 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a safety, tolerability, pharmacokinetic and efficacy study in subjects with Parkinson's disease

Conditions

  • Parkinson Disease

Interventions

  • Radotinib HCl 50 mgDrug

    Enrolled subject will continue to administer Radotinib 50mg/day, 100mg/day, 150mg/day, 200mg/day, depending on the dose level once daily for 6 months.

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of safety parameters: Adverse EventsTime frame: 12 months after dose administration

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • CHRU de Lille - Hôpital Roger Salengro

    Lille, France

  • CHU Limoges

    Limoges, France

  • CHU de Lyon HCL

    Lyon, France

  • Hôpital Nantes-Hotel Dieu

    Nantes, France

  • Hôpital Pitié-Salpêtrière

    Paris, France

  • Chu La Miletrie

    Poitiers, France

  • CHU de Rouen

    Rouen, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.